- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05822219
Vaccine Hesitancy in Black/African Americans With Rheumatic Diseases
Leveraging Community-Academic Partnerships and Social Networks to Disseminate Vaccine-Related Information and Increase Vaccine Uptake Among Black Individuals With Rheumatic Diseases.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Neil Pillai, MS
- Phone Number: 312.503.3904
- Email: neil.pillai@northwestern.edu
Study Contact Backup
- Name: Komel Safdar, MPH
- Phone Number: 312.503.0251
- Email: komel.safdar@northwestern.edu
Study Locations
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- Recruiting
- Northwestern University
-
Contact:
- Rosalind Ramsey-Goldman
- Phone Number: 312-503-0542
- Email: rgramsey@northwestern.edu
-
Contact:
- Neil Pillai, MS
- Phone Number: 3125033904
- Email: rgramsey@northwestern.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
POLs:
18-85 years old; All genders; English-speaking; Self-identify as Black and/or African descent; Received ≥1 dose of a COVID-19 vaccine after 8.31.2022 (bivalent booster or updated COVID-19 vaccine [2023-2024] formula)
Social network members:
At least 18 years of age; All genders; English-speaking or Haitian Creole or Spanish-speaking if the POL also speaks Haitian Creole or Spanish; Not have received the updated COVID-19 vaccine 2023-2024 formula; Recent (within 3 months) COVID-19 infection and either undecided or no intention of receiving the vaccine.
Exclusion Criteria:
Both POLs and social network members:
Under 18 years of age Pregnant women Institutionalized or incarcerated Those who are up to date on COVID vaccinations
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: COVID-19 vaccine and booster training
Group training involving COVID-19 vaccine and booster information, including background, development, and myths.
|
COVID-19 vaccine and booster information training
|
Experimental: COVID-19 vaccine and booster training with extra undisclosed component
Group training involving COVID-19 vaccine and booster information, including background, development, and myths.
Contains extra training component that is undisclosed until the end of the study so as not to introduce bias.
|
COVID-19 vaccine and booster information training
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Receipt of >1 COVID-19 vaccine or booster dose
Time Frame: 6 months
|
This will be measured as documentation of receipt of >1 additional COVID-19 vaccine or booster dose above network members' baseline number of doses, scored yes or no.
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in COVID-19 vaccine hesitancy
Time Frame: 6 months
|
This will be measured as the network members' absolute change in vaccine hesitancy scale score comparing 6 months to baseline between the two study arms, using the validated 10-item Likert Vaccine Hesitancy Scale, score range 10-50.
|
6 months
|
Structure and composition of the Popular Opinion Leader outreach networks.
Time Frame: 6 months
|
A mixed methods social network assessment tool will be used to compare the structures and compositions of the outreach social networks of the Popular Opinion Leaders between the two intervention arms.
This is not scored but rather used to create social network map and to understand characteristics of social networks.
|
6 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Rosalind Ramsey-Goldman, MD, DrPH, Northwestern University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Coronavirus Infections
- Coronaviridae Infections
- Nidovirales Infections
- RNA Virus Infections
- Virus Diseases
- Infections
- Respiratory Tract Infections
- Respiratory Tract Diseases
- Pneumonia, Viral
- Pneumonia
- Lung Diseases
- Musculoskeletal Diseases
- Connective Tissue Diseases
- COVID-19
- Rheumatic Diseases
- Collagen Diseases
Other Study ID Numbers
- ACTIVATE (Immune Tolerance Network)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on COVID-19
-
University of Roma La SapienzaQueen Mary University of London; Università degli studi di Roma Foro Italico; Bios Prevention SrlCompletedPost Acute Sequelae of COVID-19 | Post COVID-19 Condition | Long-COVID | Chronic COVID-19 SyndromeItaly
-
Yang I. PachankisActive, not recruitingCOVID-19 Respiratory Infection | COVID-19 Stress Syndrome | COVID-19 Vaccine Adverse Reaction | COVID-19-Associated Thromboembolism | COVID-19 Post-Intensive Care Syndrome | COVID-19-Associated StrokeChina
-
Massachusetts General HospitalRecruitingPost Acute COVID-19 Syndrome | Long COVID | Post Acute Sequelae of COVID-19 | Long COVID-19United States
-
Indonesia UniversityRecruitingPost-COVID-19 Syndrome | Long COVID | Post COVID-19 Condition | Post-COVID Syndrome | Long COVID-19Indonesia
-
Erasmus Medical CenterDa Vinci Clinic; HGC RijswijkNot yet recruitingPost-COVID-19 Syndrome | Long COVID | Long Covid19 | Post COVID-19 Condition | Post-COVID Syndrome | Post COVID-19 Condition, Unspecified | Post-COVID ConditionNetherlands
-
Dr. Soetomo General HospitalIndonesia-MoH; Universitas Airlangga; Biotis Pharmaceuticals, IndonesiaRecruitingCOVID-19 Pandemic | COVID-19 Vaccines | COVID-19 Virus DiseaseIndonesia
-
University of Witten/HerdeckeInstitut für Rehabilitationsforschung NorderneyCompletedPost-COVID-19 Syndrome | Long-COVID-19 SyndromeGermany
-
Jonathann Kuo, MDActive, not recruitingSARS-CoV2 Infection | Post-COVID-19 Syndrome | Dysautonomia | Post Acute COVID-19 Syndrome | Long COVID | Long Covid19 | COVID-19 Recurrent | Post-Acute COVID-19 | Post-Acute COVID-19 Infection | Post Acute Sequelae of COVID-19 | Dysautonomia Like Disorder | Dysautonomia Orthostatic Hypotension Syndrome | Post... and other conditionsUnited States
-
University Hospital, Ioannina1st Division of Internal Medicine, University Hospital of IoanninaRecruitingCOVID-19 Pneumonia | COVID-19 Respiratory Infection | COVID-19 Pandemic | COVID-19 Acute Respiratory Distress Syndrome | COVID-19-Associated Pneumonia | COVID 19 Associated Coagulopathy | COVID-19 (Coronavirus Disease 2019) | COVID-19-Associated ThromboembolismGreece
Clinical Trials on COVID-19 vaccine and booster training, and importance
-
Seoul National University HospitalRecruitingRenal Transplant | COVID-19 VaccinationKorea, Republic of
-
Barbara Ann Karmanos Cancer InstituteCompletedMultiple Myeloma | AL Amyloidosis | Chronic Lymphocytic LeukemiaUnited States
-
Lahore General HospitalActive, not recruitingVaccine ReactionPakistan
-
Peking Union Medical College HospitalRecruitingLung Cancer | Chemotherapy | Antibody | COVID-19 Recurrent | Vaccination | Immune Checkpoint InhibitorChina
-
ModernaTX, Inc.Active, not recruiting
-
Norwegian Institute of Public HealthNot yet recruiting
-
Hong Kong Sanatorium & HospitalCompleted
-
Thomas Jefferson UniversityWalter Reed Army Institute of Research (WRAIR); Nemours Childrens HealthRecruiting
-
University Hospital, Basel, SwitzerlandCompleted
-
Stanford UniversityViamoCompletedCOVID-19 Vaccine Knowledge | COVID-19 Vaccine BeliefsUnited States